Search research articles
Contact Us
Filters
Showing results (71-80 of 84) with videos related to
Page
of 9
Sort By:
Open Forum Infectious Diseases
|
July 10, 2025
Clinical and Health Care Resource Use Outcomes Associated With Resistance to Antiretroviral Therapy Among Veterans With HIV
S Scott Sutton, Joseph Magagnoli, Tammy H Cummings, et al.
Nature Communications
|
April 29, 2016
Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance
Alexei Brooun, Ketan S Gajiwala, Ya-Li Deng, et al.
Analytical Biochemistry
|
March 16, 2011
Study of the PDK1/AKT signaling pathway using selective PDK1 inhibitors, HCS, and enhanced biochemical assays
Alexandra Hofler, Tim Nichols, Stephan Grant, et al.
Medrxiv : the Preprint Server for Health Sciences
|
March 30, 2023
Reduction of human Alzheimer's disease risk and reversal of mouse model cognitive deficit with nucleoside analog use
Joseph Magagnoli, Praveen Yerramothu, Kameshwari Ambati, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 8, 2021
Identification of fluoxetine as a direct NLRP3 inhibitor to treat atrophic macular degeneration
Meenakshi Ambati, Ivana Apicella, Shao-Bin Wang, et al.
Nature Communications
|
September 24, 2020
Repurposing anti-inflammasome NRTIs for improving insulin sensitivity and reducing type 2 diabetes development
Jayakrishna Ambati, Joseph Magagnoli, Hannah Leung, et al.
Journal of Medicinal Chemistry
|
August 12, 2016
Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors
Pei-Pei Kung, Eugene Rui, Simon Bergqvist, et al.
Journal of Medicinal Chemistry
|
December 28, 2020
Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)
Hengmiao Cheng, Suvi T M Orr, Simon Bailey, et al.
Journal of Medicinal Chemistry
|
December 7, 2017
Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)
Pei-Pei Kung, Patrick Bingham, Alexei Brooun, et al.
Cancer Cell
|
September 14, 2021
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor
Kevin Freeman-Cook, Robert L Hoffman, Nichol Miller, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 84) with videos related to
Sort By:
Page
of 9
Open Forum Infectious Diseases
|
July 10, 2025
Clinical and Health Care Resource Use Outcomes Associated With Resistance to Antiretroviral Therapy Among Veterans With HIV
S Scott Sutton, Joseph Magagnoli, Tammy H Cummings, et al.
Nature Communications
|
April 29, 2016
Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance
Alexei Brooun, Ketan S Gajiwala, Ya-Li Deng, et al.
Analytical Biochemistry
|
March 16, 2011
Study of the PDK1/AKT signaling pathway using selective PDK1 inhibitors, HCS, and enhanced biochemical assays
Alexandra Hofler, Tim Nichols, Stephan Grant, et al.
Medrxiv : the Preprint Server for Health Sciences
|
March 30, 2023
Reduction of human Alzheimer's disease risk and reversal of mouse model cognitive deficit with nucleoside analog use
Joseph Magagnoli, Praveen Yerramothu, Kameshwari Ambati, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 8, 2021
Identification of fluoxetine as a direct NLRP3 inhibitor to treat atrophic macular degeneration
Meenakshi Ambati, Ivana Apicella, Shao-Bin Wang, et al.
Nature Communications
|
September 24, 2020
Repurposing anti-inflammasome NRTIs for improving insulin sensitivity and reducing type 2 diabetes development
Jayakrishna Ambati, Joseph Magagnoli, Hannah Leung, et al.
Journal of Medicinal Chemistry
|
August 12, 2016
Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors
Pei-Pei Kung, Eugene Rui, Simon Bergqvist, et al.
Journal of Medicinal Chemistry
|
December 28, 2020
Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)
Hengmiao Cheng, Suvi T M Orr, Simon Bailey, et al.
Journal of Medicinal Chemistry
|
December 7, 2017
Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)
Pei-Pei Kung, Patrick Bingham, Alexei Brooun, et al.
Cancer Cell
|
September 14, 2021
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor
Kevin Freeman-Cook, Robert L Hoffman, Nichol Miller, et al.
Page
of 9